Kerendia (finerenone) / Bayer - LARVOL DELTA

Letter by Kornelius Regarding Article, "Effects of the Nonsteroidal MRA Finerenone With and Without Concomitant SGLT2 Inhibitor Use in Heart Failure". (PubMed, Circulation) - No abstract available

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

Pharmacology and Therapeutic Potential of Finerenone: A Novel Third-Generation Nonsteroidal Mineralocorticoid Receptor Antagonist. (PubMed, Cureus) - "Unlike traditional steroidal MRAs such as Spironolactone and Eplerenone, Finerenone offers high selectivity for MR, resulting in reduced off-target effects, including hyperkalemia and antiandrogenic side effects. While initial results are promising, further research is necessary to evaluate the long-term outcomes and explore its full therapeutic potential, including novel applications in high-risk patients and biomarker-driven treatments. These findings position finerenone as a valuable addition to current therapies for CKD and HFrEF, though broader adoption awaits real-world validation of its safety and cost-effectiveness."

Journal • Review • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders • Nephrology • Renal Disease

CONFIDENCE in the safety and efficacy of dual therapy with an SGLT-2 inhibitor and finerenone in patients with chronic kidney disease and type 2 diabetes. (PubMed, Diabetes Obes Metab) - No abstract available

Journal • Chronic Kidney Disease • Diabetes • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Eligibility for finerenone in real-world patients with diabetes and chronic kidney disease: Insights from the FIDELITY pooled analysis. (PubMed, Nefrologia (Engl Ed)) - No abstract available

Journal • Real-world evidence • Retrospective data • Chronic Kidney Disease • Diabetes • Metabolic Disorders • Nephrology • Renal Disease

Efficacy and safety of Finerenone in Chinese patients with type 2 diabetes and chronic kidney disease not using renin-angiotensin-system inhibitors (ChiCTR) - P4 | N=180 | Not yet recruiting | Sponsor: Shanghai Sixth People's Hospital; Shanghai Sixth People's Hospital

New P4 trial • Chronic Kidney Disease • Diabetes • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Cardiovascular-Kidney-Metabolic Effects: Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists. (PubMed, Rev Cardiovasc Med) - "Moreover, the nonsteroidal MRA finerenone has demonstrated risk reductions for composite CV-related outcomes and CKD progression in patients with HF with mildly reduced or preserved ejection fraction and people with CKD associated with type 2 diabetes. Ongoing phase 3 trials are evaluating the efficacy and safety of nonsteroidal MRAs in individuals with HF and reduced ejection fraction, as well as those with mildly reduced or preserved ejection fraction, potentially expanding their role in managing CKM conditions. This review examines current clinical evidence for the use of MRAs in people with CKM syndrome."

Journal • Review • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Heart Failure • Hypertension • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

CONFIDENCE Asia: effect of simultaneous initiation of finerenone and empagliflozin on urinary albumin-to-creatinine ratio in Asian participants from the CONFIDENCE trial (EASD 2025) - P2 | "Simultaneous initiation of finerenone and an SGLT2i was effective and well-tolerated among the nearly half of participants in CONFIDENCE who were enrolled from Asia."

Late-breaking abstract • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

The mechanism of MMP-7 mediating RAAS activation associated with diabetic kidney injury through syndecan-1 pathway (EASD 2025) - "(6) Rescue experiments demonstrated: MMP-7 inhibition attenuated downstream pathway activation and renal fibrosis; SDC1 recombinant protein restored VEGF expression and fibrotic/inflammatory markers; Co-administration of finerenone (aldosterone receptor antagonist) counteracted SDC1-mediated fibroinflammatory effects. (1) Serum MMP-7 elevation in DKD patients correlates positively with renal dysfunction markers (creatinine, BUN, cystatin C, UACR, 24-hour proteinuria, TGF-β1) and inversely with eGFR... (1) Serum MMP-7 elevation in DKD patients correlates positively with renal dysfunction markers (creatinine, BUN, cystatin C, UACR, 24-hour proteinuria, TGF-β1) and inversely with eGFR. (2)MMP-7 demonstrates comparable diagnostic efficacy to UACR and eGFR, with optimal performance achieved through combined biomarker analysis. (3)MMP-7/SDC1/VEGF/RAAS axis activation in DKD models contributes to renal injury."

Late-breaking abstract • Diabetes • Metabolic Disorders • COL1A1 • COL1A2 • COL3A1 • COL5A1 • COL8A1 • CST3 • IL18 • IL1B • KIM1 • MMP7 • SDC1 • TGFB1 • TNFA • VIM

Simultaneous initiation of finerenone and empagliflozin by baseline glucagon-like peptide-1 receptor agonist use: a prespecified analysis of CONFIDENCE (EASD 2025) - P2 | "In CONFIDENCE, simultaneous initiation with finerenone and an SGLT2i was effective and well-tolerated, irrespective of background use of a GLP-1 RA."

Late-breaking abstract • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Finerenone alleviates diabetic nephropathy by improving lipid metabolism reprogramming of renal tubular epithelial cells (EASD 2025) - "Finerenone targets the ChREBP-β/ACSL4 axis to reverse lipid peroxidation in renal tubular epithelial cells and thus to alleviate kidney damage in type 2 diabetes mellitus. The study results reveal that finerenone can regulate cellular metabolism and relieve diabetic nephropathy and clarify related mechanisms."

Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus • ACSL4

Welcome and introduction: Finerenone – The Future is Now (EASD 2025) - "Sponsored By Bayer AG"

Diabetes • Metabolic Disorders

Transforming CKD care in Diabetes: Breakthroughs with Finerenone treatment (EASD 2025) - "Sponsored By Bayer AG"

Diabetes • Metabolic Disorders

An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions (clinicaltrials.gov) - P=N/A | N=50000 | Recruiting | Sponsor: Bayer | Trial completion date: Oct 2025 ➔ Mar 2026 | Trial primary completion date: Oct 2025 ➔ Mar 2026

Real-world evidence • Trial completion date • Trial primary completion date • Chronic Kidney Disease • Diabetes • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Finerenone Modulates PANoptosis to Improve Immune Microenvironment in Diabetic Nephropathy: A Machine Learning-Based Mechanistic Analysis. (PubMed, J Mol Neurosci) - "These results suggest that finerenone mitigates DN-related immune disruptions by modulating PANoptosis-linked gene expression, thereby influencing PI3K-Akt signaling and glycosphingolipid biosynthesis in mast cells, M2 macrophages, and B cells. This study provides new insights into potential therapeutic targets and pharmacological evidence for precision immunomodulation in DN treatment."

Journal • Diabetes • Diabetic Nephropathy • Immunology • Metabolic Disorders • Nephrology • Renal Disease • CASP3 • FLT3 • HIF1A • KDR • MMP2

Clinical efficacy and safety of finerenone combined with dapagliflozin in the treatment of diabetic kidney disease: a randomized controlled trial (ChiCTR) - P1 | N=52 | Completed | Sponsor: The First Affiliated Hospital of Shihezi University; The First Affiliated Hospital of Shihezi University

New P1 trial • Diabetic Nephropathy • Nephrology • Renal Disease

Pharmacological Therapy of HFrEF in 2025: Navigating New Advances and Old Unmet Needs in An Eternal Balance Between Progress and Perplexities. (PubMed, Card Fail Rev) - "This article aims to highlight the latest findings in HFrEF treatment. While emphasising the optimism these developments bring, the article also addresses the significant unresolved challenges that persist in the management of this syndrome, which remains a leading global cause of mortality, morbidity and poor quality of life with high use of resources and healthcare costs."

Journal • Review • Cardiovascular • Congestive Heart Failure • Gene Therapies • Heart Failure

Finerenone in Chronic Kidney Disease: A Comprehensive Review of Mechanisms, Efficacy and Safety. (PubMed, Diabetes Metab Res Rev) - "Future studies on their synergistic effects may provide valuable insights. Ultimately, we hope this review offers new perspectives on finerenone's clinical applications and its future therapeutic prospects."

Journal • Review • Chronic Kidney Disease • Diabetic Nephropathy • Fibrosis • Immunology • Inflammation • Nephrology • Renal Disease

Proteinuria reduction by and safety of finerenone in Chinese patients with CKD without diabetes: a real-world retrospective study. (PubMed, BMC Urol) - "Finerenone treatment significantly reduced proteinuria over the follow-up period, with minimal effects on potassium and the eGFR being observed, thereby supporting its safety and efficacy in the treatment of CKD patients without DM."

Journal • Real-world evidence • Retrospective data • Chronic Kidney Disease • Diabetes • Glomerulonephritis • Metabolic Disorders • Nephrology • Renal Disease

An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Care in the United States (clinicaltrials.gov) - P=N/A | N=150000 | Active, not recruiting | Sponsor: Bayer | Trial completion date: Jun 2025 ➔ Dec 2025 | Trial primary completion date: Jun 2025 ➔ Dec 2025

Trial completion date • Trial primary completion date • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Kidney protection: role of sodium-glucose co-transporter 2 inhibitors and finerenone (PubMed, G Ital Cardiol (Rome)) - "Initially in diabetic patients and later in those suffering from heart failure and chronic kidney disease, these new drugs have demonstrated their effectiveness in reducing cardiovascular risk, the progression of heart failure and chronic kidney disease. This review aims to address the main pharmacological aspects of two of these new classes, that of sodium-glucose co-transporter 2 inhibitors and the more recent one of non-steroidal mineralocorticoid receptor antagonists."

Journal • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Diabetic Nephropathy • Heart Failure • Metabolic Disorders • Nephrology • Renal Disease

Blinded Withdrawal of Finerenone After Long-Term Treatment in the FINEARTS-HF Trial. (PubMed, J Am Coll Cardiol) - No abstract available

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary Analysis. (PubMed, Diabetes Care) - "In participants with T2D and CKD, consistent benefits of semaglutide on major kidney outcomes, MACE, and all-cause mortality were observed regardless of baseline MRA use."

Journal • Cardiovascular • Chronic Kidney Disease • Diabetes • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Effect and Safety of Finerenone in Patients with IgA Nephropathy. (PubMed, J Inflamm Res) - "Serum potassium and creatinine levels remained stable, and no adverse events related to hyperkalemia were observed. The retrospective evaluation suggests that finerenone combined with RASI effectively reduced proteinuria in IgA nephropathy patients, underscoring its potential as a viable treatment option for this patient population."

Journal • Glomerulonephritis • IgA Nephropathy • Renal Disease

The Steno 1 study: Multifactorial intervention to reduce cardiovascular disease in type 1 diabetes-rationale and protocol of the prospective, randomized, open-labelled multicentre study. (PubMed, Diabetes Obes Metab) - "The Steno 1 study will determine whether MFI is superior to standard care with respect to MACE, HHF progression of CKD, and mortality in individuals with type 1 diabetes and high risk of CVD."

Journal • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Diabetic Nephropathy • Genetic Disorders • Heart Failure • Metabolic Disorders • Nephrology • Obesity • Renal Disease • Type 1 Diabetes Mellitus

The New Horizon: A Viewpoint of Novel Drugs, Biomarkers, Artificial Intelligence, and Self-Management in Improving Kidney Transplant Outcomes. (PubMed, J Clin Med) - "Drugs, such as SGLT2 inhibitors and finerenone, have demonstrated improved outcomes in patients but lack comprehensive long-term evidence in KTx patients. The use of biomarkers, including circulating cytokines and transcriptomics, coupled with AI, could enhance early detection and personalized treatment strategies. Addressing patient self-management and addressing health access disparities may be more achievable using technologies used at home rather than traditional models of healthcare and thus lead to increased transplant success, both in terms of transplantation rates and allograft longevity."

Biomarker • Journal • Chronic Kidney Disease • Nephrology • Renal Disease • Transplantation